PCN10 A MATCH-ADJUSTED INDIRECT TREATMENT COMPARISON (MAIC) OF LENALIDOMIDE PLUS RITUXIMAB (R2) VERSUS RITUXIMAB PLUS CHEMOTHERAPY (R-CHEMO) FOR RELAPSED AND/OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)

Autor:	F. Hernandez-Ilizaliturri, S. Abouzaid, C. Parker, A. Tabah, L. Arcaini, E. Bachy, C. Fox, C.L. Watkins, J. Jones
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty Chemotherapy business.industry Health Policy medicine.medical_treatment Public Health Environmental and Occupational Health Follicular lymphoma medicine.disease Refractory Indirect Treatment Internal medicine medicine Rituximab business Lenalidomide medicine.drug
Zdroj:	Value in Health. 22:S436-S437
ISSN:	1098-3015
DOI:	10.1016/j.jval.2019.09.207
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::fc291db26403f631bdfc2c24e79d5425 https://doi.org/10.1016/j.jval.2019.09.207 Zobrazit plný text záznamu Full Text from ScienceDirect